Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell carcinoma (BCC). Vismodegib, a first-in-class small-molecule inhibitor of hedgehog pathway signaling, is approved by regulatory authorities for the treatment of adults who have metastatic BCC or local...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacouture, Mario E., Dréno, Brigitte, Ascierto, Paolo Antonio, Dummer, Reinhard, Basset-Seguin, Nicole, Fife, Kate, Ernst, Scott, Licitra, Lisa, Neves, Rogerio I., Peris, Ketty, Puig, Susana, Sokolof, Jonas, Sekulic, Aleksandar, Hauschild, Axel, Kunstfeld, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061532/
https://www.ncbi.nlm.nih.gov/pubmed/27511905
http://dx.doi.org/10.1634/theoncologist.2016-0186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061532/
https://www.ncbi.nlm.nih.gov/pubmed/27511905
http://dx.doi.org/10.1634/theoncologist.2016-0186

Ejemplares similares